Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 3/20 | 0.42 |
| ▸ | RARB | P10826 | 3/20 | 0.42 |
| ▸ | RARG | P13631 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.42 |
| ▸ | GOT1 | P17174 | 1/20 | 0.42 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8112537 | 0.87 | RARA (0.40) | RARARARBRARGLMNATDP1 | |
| SCHEMBL9318559 | 0.80 | HDAC11 (0.41) | RARARARBRARGLMNATDP1 | |
| SCHEMBL23071384 | 0.79 | ALDH1A1 (0.38) | RARARARBRARGLMNATDP1 | |
| SCHEMBL17847394 | 0.79 | IKBKB (0.36) | RARALMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL8910587 | 0.79 | — | — | |
| SCHEMBL8648962 | 0.79 | IKBKB (0.49) | RARARARBRARGLMNAMEN1 | |
| SCHEMBL8648956 | 0.78 | IKBKB (0.33) | RARA | |
| SCHEMBL8648960 | 0.78 | — | — | |
| SCHEMBL31027152 | 0.76 | CNR2 (0.48) | RARARARBRARGLMNATDP1 | |
| SCHEMBL647856 | 0.76 | CNR2 (0.48) | RARARARBRARGLMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249713-A1 | Prevention of Retinopathy by Inhibition of the Visual Cycle | LARSEN LARS M | 2007-10-25 | — | — | US | claimed |
| CN-1964706-A | Prevention of retinopathy by inhibition of visual cycle | MICHAEL LARSEN LARS (DK) | 2007-05-16 | — | — | CN | claimed |
| EP-1727529-A2 | PREVENTION OF RETINOPATHY BY INHIBITION OF THE VISUAL CYCLE | Larsen, Lars, Michael (DK) | 2006-12-06 | — | — | EP | claimed |
| WO-2005087210-A2 | PREVENTION OF RETINOPATHY BY INHIBITION OF THE VISUAL CYCLE | LARSEN LARS MICHAEL (DK) | 2005-09-22 | — | — | WO | claimed |
| EP-0376852-A1 | Microgranules essentially consisting of triglycerides of saturated fatty acids loaded with an active substance, and their topical therapeutical use | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1990-07-04 | — | — | EP | claimed |
| CN-115996920-A | Nonlinear optical chromophores comprising adamantyl-like groups | 光波逻辑有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-9421175-B2 | Prevention of retinopathy by inhibition of the visual cycle | LARSEN LARS MICHAEL (DK) | 2016-08-23 | — | — | US | disclosed |
| EP-1727529-B1 | PREVENTION OF RETINOPATHY BY INHIBITION OF THE VISUAL CYCLE | LARSEN LARS MICHAEL (DK) | 2016-03-02 | — | — | EP | disclosed |
| EP-2139838-B1 | A PROCESS FOR THE PREPARATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTOIC ACID | GRINDEKS JSC (LV) | 2012-03-28 | — | — | EP | disclosed |
| CN-1696100-B | Now short cutting method for synthcsizing Adpalin dryg trcatubg acnc | HEILONGJIANG FUHE HUAXING PHARMACY GROUP CO LTD | 2010-11-24 | — | — | CN | disclosed |
| US-20100160677-A1 | PROCESS FOR PREPARATION OF 6-[3-(1-ADMANTYL)-4-METHOXYPHENYL]-2-NAPHTOIC ACID. | JSC GRINDEKS (LV) | 2010-06-24 | — | — | US | disclosed |
| EP-2139838-A2 | A PROCESS FOR THE PREPARATION OF 6-Ý3-(1-ADAMANTYL)-4-METHOXYPHENYL-2-NAPHTOIC ACID | Grindeks, a joint stock company (LV) | 2010-01-06 | — | — | EP | disclosed |
| WO-2005087210-A2 | PREVENTION OF RETINOPATHY BY INHIBITION OF THE VISUAL CYCLE | LARSEN LARS MICHAEL (DK) | 2005-09-22 | — | — | WO | disclosed |
| EP-0584191-B1 | NOVEL AROMATIC AND POLYCYCLIC COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | CIRD GALDERMA (FR) | 1997-08-13 | — | — | EP | disclosed |
| EP-0552282-B1 | BI-AROMATIC COMPOUNDS AND THEIR USE IN HUMAN AND VETERINARY MEDECINE AND IN COSMETIC PREPARATIONS | CIRD GALDERMA (FR) | 1994-08-24 | — | — | EP | disclosed |
| EP-0584191-A1 | NOVEL AROMATIC AND POLYCYCLIC COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDECINE AND IN COSMETICS. | CIRD GALDERMA (FR) | 1994-03-02 | — | — | EP | disclosed |
| EP-0552282-A1 | BI-AROMATIC COMPOUNDS AND THEIR USE IN HUMAN AND VETERINARY MEDECINE AND IN COSMETIC PREPARATIONS. | CIRD GALDERMA (FR) | 1993-07-28 | — | — | EP | disclosed |
| WO-1992019583-A1 | NOVEL AROMATIC AND POLYCYCLIC COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDECINE AND IN COSMETICS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1992-11-12 | — | — | WO | disclosed |
| WO-1992006948-A1 | BI-AROMATIC COMPOUNDS AND THEIR USE IN HUMAN AND VETERINARY MEDECINE AND IN COSMETIC PREPARATIONS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1992-04-30 | — | — | WO | disclosed |
| EP-0463962-A1 | Preparation of fatty product microspheres loaded or not with an active substance | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249713-A1 | Prevention of Retinopathy by Inhibition of the Visual Cycle | VEGFA, HIF1AN, ALDH1A2 | RARA 121/4885RARB 74/4885RARG 44/4885 |
| US-20100160677-A1 | PROCESS FOR PREPARATION OF 6-[3-(1-ADMANTYL)-4-METHOXYPHENYL]-2-NAPHTOIC ACID. | ME1, CD274, PDCD1LG2 | RARA 2036/4885RARB 2961/4885RARG 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.